prediction
HanAll Biopharma is forecast to post 2026 revenue of 169.3 billion KRW, operating profit of 12.0 billion KRW, and an operating margin of 7.1%.
A prediction by report author. Statements are as reported by the cited publishers — not verified by DecisionGateway.
2026년 매출 169.3십억원 / 영업이익 12.0십억원 / 영업이익률 7.1%
Related claims
HanAll Biopharma is forecast to post 2027 revenue of 177.3 billion KRW, operating profit of 10.6 billion KRW, and an operating margin of 6.0%.report author · predictionRFHIC's financial forecasts are: 2025 revenue 185.8 billion won, operating profit 30.9 billion won, operating margin 16.6%; 2026 revenue 262.1 billion won, operating profit 62.7 billion won, operating margin 23.9%; 2027 revenue 318.0 billion won, operating profit 75.3 billion won, operating margin 23.7%.report author · prediction2026 consolidated revenue is forecast at 4.5459 trillion KRW and operating profit at 1.263 trillion KRW.하나증권 · predictionQ4 2026 results are forecast at revenue of 510.2 billion KRW (YoY +3%, QoQ -9%) and an operating loss of 10.3 billion KRW, a swing to loss for the first time in eight quarters.하나증권 · prediction2026년 매출 7,156.1십억원 / 영업이익 782.0십억원 / 영업이익률 10.9%를 기록할 것으로 전망된다.리포트 작성자 · prediction2026년 매출 3,853.2억원 / 영업이익 403.4억원 / 영업이익률 10.47%가 예상된다.companyreport · prediction